Condition or disease | Intervention/treatment |
---|---|
Depression Depressive Disorder Depressive Disorder, Major Depressive Episode | Device: intermittent theta burst stimulation (iTBS) |
The immense disease burden of major depressive disorder (MDD) and unsatisfactory response rates to pharmacological and psychological interventions highlight the need for further development of treatment alternatives. The development of these alternatives relies on an understanding of the pathophysiology of depression, which has, despite considerable efforts, remained largely elusive. Findings have converged on the proposition that depression cannot be attributed to a singular factor and is better understood as a dysfunctional interaction of multiple parameters. At the neural level, depression is described as a dysfunction of several cortical and sub-cortical networks associated with affective salience, cognitive control and self-reverential thoughts. Encouragingly, several studies have shown that pathological alterations in one of these networks, the Default Mode network, may normalize following several weeks of treatment using repetitive transcranial magnetic stimulation (rTMS), an accepted treatment for major depression.
The present study aims to elucidate the time course of this modulatory effect on the different networks showing pathological connectivity profiles. Specifically, our aim is to obtain several measurements of functional connectivity and concomitant measures of the symptoms of depression prior to, throughout, and following the 4 week treatment course of iTBS, a faster but equally effective non-invasive brain stimulation technique compared to rTMS. Due to the fact that weekly changes in network connectivity are expected to be relatively small, the stronger BOLD Signal at 7T and the fact that peak temporal correlation coefficients calculated between network nodes have been shown to be significantly higher at 7T than 3T (e.g.) in the Default Mode network should greatly aid in detecting these differences. At each of the 7 measurement time points, fluctuations of BOLD signal will be recorded during a rs-fMRI scan lasting about 15 minutes. Our approach will allow to characterize the temporal profiles of the antidepressant effects of iTBS, thereby furthering our understanding of the mechanism by which iTBS contributes to the normalization of pathological neural connectivity and the reduction of depression symptoms. This proposed longitudinal functional imaging of therapeutic changes is highly relevant to the field of clinical neuroscience and should further advance our understanding of the pathophysiology of depression.
Study Type : | Observational |
Estimated Enrollment : | 60 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Resting-state Functional Connectivity Throughout a Course of iTBS in Major Depression |
Actual Study Start Date : | July 23, 2018 |
Estimated Primary Completion Date : | February 1, 2020 |
Estimated Study Completion Date : | June 1, 2020 |
Group/Cohort | Intervention/treatment |
---|---|
MDD patients |
Device: intermittent theta burst stimulation (iTBS)
20 sessions of iTBS
|
Healthy controls |
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Outpatients at the psychiatric hospital of the University Hospital Bonn. The patients diagnosis of major depressive disorder will be verified via the structured clinical interview for DSM-5. iTBS protocols in line with international standards administered by a trained professional.
Additionally, a healthy control sample is included in the study.
Inclusion Criteria:
Exclusion Criteria:
Contact: Clemens Mielacher, Mag. | +49 228 287 11519 | clemens.mielacher@ukbonn.de | |
Contact: Maximilian Kiebs, M.Sc. | +49 228 287 19710 | m.kiebs@ukbonn.de |
Germany | |
Klinik und Poliklinik für Psychiatrie und Psychotherapie | Recruiting |
Bonn, Germany | |
Contact: Clemens Mielacher, Mag. +49 228 287 11519 clemens.mielacher@ukbonn.de | |
Contact: Maximilian Kiebs, M.Sc. +49 228 287 19710 m.kiebs@ukbonn.de |
Principal Investigator: | René Hurlemann, Prof. | University Hospital, Bonn |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | May 7, 2019 | ||||
First Posted Date | May 9, 2019 | ||||
Last Update Posted Date | May 9, 2019 | ||||
Actual Study Start Date | July 23, 2018 | ||||
Estimated Primary Completion Date | February 1, 2020 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
Change in functional connectivity coefficients based on rs-fMRI over 7 timepoints. [ Time Frame: Six weekly measurements starting 1 week before first iTBS treatment session, one follow-up measurement four weeks after last measurement. ] Seed-to-voxel functional connectivity analysis of rs-fMRI data.
|
||||
Original Primary Outcome Measures | Same as current | ||||
Change History | No Changes Posted | ||||
Current Secondary Outcome Measures |
Change in depression severity as measured by the Hamilton Depression Rating Scale (HDRS-17) over 7 timepoints. [ Time Frame: Six weekly measurements starting 1 week before first iTBS treatment session, one follow-up measurement four weeks after last measurement. ] Remission defined as HDRS-17 score (range: 0 to 52) of less than or equal to 8 after the iTBS course. Response defined as a reduction of at least 50% from baseline in HDRS-17 score after treatment.
|
||||
Original Secondary Outcome Measures | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | Resting-state Functional Connectivity Throughout a Course of iTBS in Major Depression | ||||
Official Title | Resting-state Functional Connectivity Throughout a Course of iTBS in Major Depression | ||||
Brief Summary | This study aims to investigate changes in functional connectivity over a four week treatment course with intermittent theta burst stimulation (iTBS) in patients with major depressive disorder (MDD). To this end, seven weekly resting-state fMRI (rs-fMRI) scans at 7 tesla (7T) will precede, accompany and follow the iTBS treatment course. By obtaining several samples of the modulatory effects of iTBS on functional connectivity networks and simultaneous measurements of the depressive symptoms it will be possible to assess the time course of changes in connectivity across different networks, and to assess the overall relationship between the network modulation and the antidepressant effects of the treatment over time. | ||||
Detailed Description |
The immense disease burden of major depressive disorder (MDD) and unsatisfactory response rates to pharmacological and psychological interventions highlight the need for further development of treatment alternatives. The development of these alternatives relies on an understanding of the pathophysiology of depression, which has, despite considerable efforts, remained largely elusive. Findings have converged on the proposition that depression cannot be attributed to a singular factor and is better understood as a dysfunctional interaction of multiple parameters. At the neural level, depression is described as a dysfunction of several cortical and sub-cortical networks associated with affective salience, cognitive control and self-reverential thoughts. Encouragingly, several studies have shown that pathological alterations in one of these networks, the Default Mode network, may normalize following several weeks of treatment using repetitive transcranial magnetic stimulation (rTMS), an accepted treatment for major depression. The present study aims to elucidate the time course of this modulatory effect on the different networks showing pathological connectivity profiles. Specifically, our aim is to obtain several measurements of functional connectivity and concomitant measures of the symptoms of depression prior to, throughout, and following the 4 week treatment course of iTBS, a faster but equally effective non-invasive brain stimulation technique compared to rTMS. Due to the fact that weekly changes in network connectivity are expected to be relatively small, the stronger BOLD Signal at 7T and the fact that peak temporal correlation coefficients calculated between network nodes have been shown to be significantly higher at 7T than 3T (e.g.) in the Default Mode network should greatly aid in detecting these differences. At each of the 7 measurement time points, fluctuations of BOLD signal will be recorded during a rs-fMRI scan lasting about 15 minutes. Our approach will allow to characterize the temporal profiles of the antidepressant effects of iTBS, thereby furthering our understanding of the mechanism by which iTBS contributes to the normalization of pathological neural connectivity and the reduction of depression symptoms. This proposed longitudinal functional imaging of therapeutic changes is highly relevant to the field of clinical neuroscience and should further advance our understanding of the pathophysiology of depression. |
||||
Study Type | Observational | ||||
Study Design | Observational Model: Case-Control Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Not Provided | ||||
Sampling Method | Non-Probability Sample | ||||
Study Population |
Outpatients at the psychiatric hospital of the University Hospital Bonn. The patients diagnosis of major depressive disorder will be verified via the structured clinical interview for DSM-5. iTBS protocols in line with international standards administered by a trained professional. Additionally, a healthy control sample is included in the study. |
||||
Condition |
|
||||
Intervention | Device: intermittent theta burst stimulation (iTBS)
20 sessions of iTBS
|
||||
Study Groups/Cohorts |
|
||||
Publications * |
|
||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Unknown status | ||||
Estimated Enrollment |
60 | ||||
Original Estimated Enrollment | Same as current | ||||
Estimated Study Completion Date | June 1, 2020 | ||||
Estimated Primary Completion Date | February 1, 2020 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria |
Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender |
|
||||
Ages | 18 Years to 60 Years (Adult) | ||||
Accepts Healthy Volunteers | Yes | ||||
Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries | Germany | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT03944213 | ||||
Other Study ID Numbers | DepRest | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement |
|
||||
Responsible Party | Rene Hurlemann, University Hospital, Bonn | ||||
Study Sponsor | University Hospital, Bonn | ||||
Collaborators |
|
||||
Investigators |
|
||||
PRS Account | University Hospital, Bonn | ||||
Verification Date | May 2019 |